Sharon Pine, Ph.D.
Rutgers, The State University of New Jersey-RBHS-CINJ
Funded by LUNG FORCE
Treating PI3 kinase-mutant NSCLC
Lung cancer is responsible for 25 percent of deaths caused by any cancer in the US. Most patients with lung cancer are diagnosed after the cancer has already spread and, unfortunately, the options for therapy are very few. Some patients with lung adenocarcinoma are eligible for therapy that targets the mutation in their tumor. However, there are still no targeted therapies available for most patients with lung squamous cell carcinoma. Our proposal addresses this problem. We propose to test a novel way to treat squamous cell carcinomas that have a mutation in the gene called PIK3CA. A mutation in PIK3CA is believed to be the "driver" of the tumor. We propose pre-clinical pilot studies to examine a new treatment options for these patients. Our long-term goal is to make targeted therapy a reality for all lung cancer patients. We believe our proposed work will bring us closer to that goal and will ultimately improve survival for patients with lung cancer.
Sign up for the latest lung health news delivered right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.